Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87953 | 0.95 | GSK3B (0.60) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL88085 | 0.94 | GSK3B (0.59) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL88324 | 0.94 | GSK3B (0.59) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL87833 | 0.94 | GSK3B (0.59) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL87840 | 0.92 | GSK3B (0.58) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL88125 | 0.92 | GSK3B (0.58) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL87934 | 0.91 | GSK3B (0.56) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL88166 | 0.89 | GSK3B (0.55) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL88187 | 0.88 | GSK3B (0.53) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL88360 | 0.88 | GSK3B (0.60) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | claimed |
| EP-1805164-A2 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Pharma Corporation (JP) | 2007-07-11 | — | — | EP | claimed |
| WO-2006036015-A2 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2006-04-06 | — | — | WO | claimed |
| US-8129377-B2 | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129377-B2 | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129377-B2 | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-1805164-B9 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-09-07 | — | — | EP | disclosed |
| EP-1805164-B1 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2266969-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266969-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2261224-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261224-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| WO-2006036015-A2 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, PSEN1 | GSK3B 89/4885CYP2D6 1266/4885CYP1A2 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.